App-Quantinova.ai

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Joseph M. Connors - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

A Critical Role for Intratumoral and Circulating LAG3 in Classical Hodgkin Lymphoma: Analysis from the Rathl Prospective Phase III International Clinical Trial

Emad Uddin Abro - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

N/A

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

John Radford - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Peripheral neuropathy

N/A

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Jonathon B. Cohen - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Nivolumab

Structure Guided Engineering of Highly Specific Chimeric Antigen Receptors for the Treatment of T Cell Lymphomas

Shimobi Onuoha - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

T-cell lymphoma

N/A

The Novel HDAC Inhibitor Chidamide Synergizes with Rituximab to Inhibit DLBCL Tumor Growth in Vitro and In Vivo By up-Regulating CD20 Expression

Xu-Wen Guan - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Chidamide

Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study

Kirit Ardeshna - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

daratumumab Intravenous

New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease

Luca Aresu - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Laurie H Sehn - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Polatuzumab vedotin

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Marie Maerevoet - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Selinexor

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial

Alison J. Moskowitz - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Adcetris

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Michael Dickinson - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Molibresib

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Gemcitabine

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Vincent Ribrag - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Tazemetostat

Does Life-Expectancy in Patients with Diffuse Large B-Cell Lymphoma Return to Normal? Findings from a UK-Based Population-Based Study

Russell Patmore - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement

Toby A. Eyre - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Validation Study of Logistic Regression in Classifying Primary Vitreoretinal Lymphoma Vs. Uveitis By IL-6 and IL-10 Levels

David Kuo - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Interleukin-10

Filters

45280 Abstracts